Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Drug-drug interactions between vitamin K antagonists and statins: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Use of prescription drugs in the older adult population-a nationwide pharmacoepidemiological study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The effects of 2 weeks of statin treatment on mitochondrial respiratory capacity in middle-aged males: the LIFESTAT study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Quality assessment of structure and language elements of written responses given by seven Scandinavian drug information centres

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Thromboembolic and bleeding complications following primary total knee arthroplasty: a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Discontinuation of diabetes medication in the 10 years before death in Denmark: a register-based study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Validation of registration of pharmacological treatment in the Danish Hip and Knee Arthroplasty Registers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

PURPOSE: A rapidly increasing use of biological drugs has led to substantial costs. Shift to biosimilars enables considerable reduction of these costs without jeopardizing the treatment of patients, but most countries have extensive possibilities of untapped cost-savings. The aim of this study was to describe the Danish quick and near-complete implementation of the two first TNF inhibitor biosimilars (infliximab and etanercept).

METHODS: We shed light on the considerations and experiences made during the implementation, and present key figures from the implementation.

RESULTS: The infliximab biosimilar constituted 90.6% of the total amount of infliximab four months following patent expiration of the biooriginator. Similar results were seen for etanercept biosimilar. Substantial cost reductions were experienced in the way that e.g. the infliximab-shift reduced cost by two thirds.

CONCLUSION: We believe that a thorough preparation and an organizational setting supporting the implementation is crucial for the successful implementation. This same implementation model will be used for future biosimilars.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Clinical Pharmacology
Vol/bind76
Udgave nummer1
Sider (fra-til)35-40
Antal sider6
ISSN0031-6970
DOI
StatusUdgivet - jan. 2020

ID: 58296606